Katri S Selander
Overview
Explore the profile of Katri S Selander including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
970
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Saarela M, Parviainen E, Lleo A, Di Tommaso L, Raunio H, Kankaanranta K, et al.
BMC Immunol
. 2025 Jan;
26(1):4.
PMID: 39844069
Vanishing bile duct syndrome (VBDS) is a serious drug induced liver injury characterized by chronic cholestasis and loss of intrahepatic bile ducts. VBDS has been reported also following checkpoint inhibitor...
2.
Petruk N, Siddiqui A, Tadayon S, Maatta J, Mattila P, Jukkola A, et al.
Front Immunol
. 2023 Aug;
14:1179022.
PMID: 37533856
Introduction: Bisphosphonates (BPs) are bone-protecting osteoclast inhibitors, typically used in the treatment of osteoporosis and skeletal complications of malignancies. When given in the adjuvant setting, these drugs may also prevent...
3.
Petruk N, Tuominen S, Akerfelt M, Mattsson J, Sandholm J, Nees M, et al.
Sci Rep
. 2021 Mar;
11(1):6035.
PMID: 33727591
CD73 is a cell surface ecto-5'-nucleotidase, which converts extracellular adenosine monophosphate to adenosine. High tumor CD73 expression is associated with poor outcome among triple-negative breast cancer (TNBC) patients. Here we...
4.
Chandler M, Keene K, Tuomela J, Forero-Torres A, Desmond R, Vuopala K, et al.
PLoS One
. 2017 Sep;
12(9):e0183832.
PMID: 28886076
Introduction: Toll-like receptor 9 (TLR9) is an innate immune system DNA-receptor that regulates tumor invasion and immunity in vitro. Low tumor TLR9 expression has been associated with poor survival in...
5.
Jamil M, Jerome M, Miley D, Selander K, Robert F
Lung Cancer (Auckl)
. 2017 Jun;
8:39-44.
PMID: 28652837
Purpose: Malignant pleural mesothelioma (MPM) is a rare malignancy with a dismal median survival of <12 months with current therapy. Single and combination chemotherapy regimens have shown only modest clinical...
6.
Sandholm J, Lehtimaki J, Ishizu T, Velu S, Clark J, Harkonen P, et al.
Oncotarget
. 2016 Nov;
7(52):87373-87389.
PMID: 27888633
Bisphosphonates are standard treatments for bone metastases. When given in the adjuvant setting, they reduce breast cancer mortality and recurrence in bone but only among post-menopausal patients. Optimal drug use...
7.
Tuomela J, Sandholm J, Kaakinen M, Hayden K, Haapasaari K, Jukkola-Vuorinen A, et al.
Breast Cancer Res Treat
. 2016 Jan;
155(2):261-71.
PMID: 26780557
Toll-like receptor 9 (TLR9) is a cellular DNA-receptor widely expressed in cancers. We previously showed that synthetic and self-derived DNA fragments induce TLR9-mediated breast cancer cell invasion in vitro. We...
8.
Mella M, Kauppila J, Karihtala P, Lehenkari P, Jukkola-Vuorinen A, Soini Y, et al.
Oncoimmunology
. 2015 Jul;
4(6):e1002726.
PMID: 26155410
Toll-like receptor 9 (TLR9) is a cellular DNA-receptor of the innate immune system that is widely expressed in cancers. We demonstrated that low tumor TLR9 expression predicts poor disease-specific survival...
9.
Kauppila J, Korvala J, Siirila K, Manni M, Makinen L, Hagstrom J, et al.
J Oral Pathol Med
. 2014 Oct;
44(8):571-7.
PMID: 25338738
Background: Toll-like receptor 9 (TLR9) is a cellular receptor, which recognizes bacterial and host-derived DNA. Stimulation of TLR9 induces cellular invasion via matrix metalloproteinase 13 (MMP-13). The aim of this...
10.
Sandholm J, Selander K
Front Immunol
. 2014 Aug;
5:330.
PMID: 25101078
Toll-like receptor 9 (TLR9) is a cellular DNA receptor of the innate immune system. DNA recognition via TLR9 results in an inflammatory reaction, which eventually also activates a Th1-biased adaptive...